Extrahepatic cholangiocarcinoma: Genomic variables associated with anatomic location and outcome Journal Article
| Authors: | Preston, W. A.; Drill, E.; Boerner, T.; Gelfer, R.; Harding, J. J.; O'Reilly, E. M.; Cercek, A.; Abou-Alfa, G.; Park, W.; Balachandran, V. P.; Drebin, J.; Soares, K. C.; Wei, A.; Kingham, T. P.; D'Angelica, M. I.; Jarnagin, W. R. |
| Article Title: | Extrahepatic cholangiocarcinoma: Genomic variables associated with anatomic location and outcome |
| Abstract: | PURPOSE: This study aimed to define genomic differences between perihilar cholangiocarcinoma (PCA) and distal cholangiocarcinoma (DCA) and identify genomic determinants of survival.MATERIALS AND METHODSConsecutive patients with ECA with tissue for targeted next-generation sequencing were analyzed, stratified by anatomic site (PCA/DCA), disease extent, and treatment. Associations between genomic alterations, clinicopathologic features, and outcomes were analyzed using Cox proportional hazards regression to compare survival. RESULTS In total, 224 patients diagnosed between 2004 and 2022 (n = 127 PCA; n = 97 DCA) met inclusion criteria. The median survival was 29 months (43 after resection and 17 from diagnosis for unresectable disease). Compared with PCA, DCA was enriched in TP53alt (alterations; 69% v 33%; Q < 0.01), epigenetic pathway alterations (45% v 29%; Q = 0.041), and had more total altered pathways (median 3 v 2; Q < 0.01). KRASalt frequency was similar between PCA (36%) and DCA (37%); however, DCA was enriched in KRAS G12D (19% v 9%; P =.002). No other clinicopathologic or genomic variables distinguished subtypes. In resected patients, no genomic alterations were associated with outcome. However, in unresectable patients, CDKN2Aalt (hazard ratio [HR], 2.59 [1.48 to 4.52]) and APCalt (HR, 5.11 [1.96 to 13.3]) were associated with reduced survival. For the entire cohort, irresectability (HR, 3.13 [2.25 to 4.36]), CDKN2Aalt (HR, 1.80 [1.80 to 2.68]), and APCalt (HR, 2.00 [1.04 to 3.87]) were associated with poor survival. CONCLUSION CDKN2Aalt and APCalt were associated with poor survival in ECA, primarily in advanced disease. As PCA and DCA were genetically similar, coanalysis of PCA and DCA in future genomic studies is reasonable. © 2024 American Society of Clinical Oncology. |
| Journal Title: | JCO Precision Oncology |
| Volume: | 8 |
| Issue: | 1 |
| ISSN: | 2473-4284 |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-07-01 |
| Start Page: | e2400206 |
| Language: | English |
| DOI: | 10.1200/po.24.00206 |
| PUBMED: | 38986041 |
| PROVIDER: | scopus |
| PMCID: | PMC11239138 |
| DOI/URL: | |
| Notes: | Article -- MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PubMed and PDF -- MSK corresponding author is William Jarnagin -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work